Helix Acquisition filed a shelf registration for the resale of up to 11.5 million PIPE shares. The SPAC is in a pending merger with MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on therapies for inflammatory skin and joint diseases.
In addition to the $115 million held in Helix Acquisition’s trust (assuming no redemptions), the transaction also includes the $115 million PIPE, which in January was being led by the SPAC’s sponsor Cormorant Asset Management. Read more.
